Endometrial Cancer Market Research Report – Forecast to 2027

Global Endometrial Cancer Market Research Report, by Diagnosis (Pelvic Examination, Transvaginal Ultrasound, Endometrial Biopsy), Treatment (Hysterectomy, Radiation), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2027

ID: MRFR/MED/4765-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The abnormal growth of endometrium cells in the uterus is termed as endometrial cancer which is also known as uterine cancer. Endometrial cancer is diagnosed at an early stage as women experience abnormal vaginal bleeding. It is reported that endometrial cancer is the sixth most common cancer in women all over the world. The endometrial cancer market is expected to witness a tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market.  Diabetes is another risk factor that leads to the development of endometrial cancer. According to the American Cancer Society,  endometrial cancer is four times common in diabetic women than in normal women. Such factors contribute to endometrial cancer among women.


However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global endometrial cancer market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.


Segmentation


The global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin, and cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.     


On the basis of region, the global endometrial cancer market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the global endometrial cancer market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.


Regional Market Summary


The endometrial cancer market is dominated by North America owing to the rising prevalence of breast cancer. The US Breast Cancer Statistics projected 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in 2018. Other factors such as increasing healthcare expenditure and increasing obesity within the female population drive the market growth in this region.


It is estimated that Europe stood second in the global endometrial cancer market owing to the increasing prevalence of ovarian cancer in this region. According to the Cancer Research UK in 2015, 7270 new cases of ovarian cancer were registered in the UK. Thus, the increasing prevalence of ovarian cancer in this region influences the growth of this market in this region.


Asia-Pacific was projected to be the fastest growing region for the global endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the American Diabetes Association, diabetes in South Asia is expected to rise by 150% from 2000 to 2035. This provides a favorable background for the market to grow.


The Middle East and Africa holds the least share in the global endometrial cancer market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.


Global Endometrial Cancer Market Share (%), by Region, 2017


 Endometrial Cancer Market Share

Sources: World Cancer Research Fund International, the American Cancer Society, Inc, Center for Disease Control and Prevention


Global Endometrial Cancer Market, by Diagnosis



  • Pelvic examination

  • Transvaginal ultrasound

  • Endometrial biopsy

  • Dilation and curettage (D&C)

  • Diagnostic laparoscopy


Global Endometrial Cancer Market, by Treatment



  • Hysterectomy Techniques

    • Open abdominal hysterectomy

    • Total vaginal hysterectomy

    • Total laparoscopic hysterectomy

    • Robotic hysterectomy



  • Radiation

    • External radiation

    • Internal radiation (brachytherapy)



  • Hormone therapy

    • Progestins

    • Tamoxifen

    • Luteinizing hormone-releasing hormone agonists

    • Aromatase inhibitors



  • Chemotherapy

    • Paclitaxel

    • Carboplatin

    • Doxorubicin

    • Cisplatin



  • Palliative care


Global Endometrial Cancer market, by End-User



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Gynecology Centers

  • Feminist Health Centers


Global Endometrial Cancer Market, by Region



  • The Americas

  • Europe

  • Asia-Pacific

  • The Middle East & Africa


Global Endometrial Cancer Market, by Key Players



  • Pfizer Inc.

  • General Electric Company

  • Koninklijke Philips N.V.

  • LUPIN, PHYTON

  • Bayer AG

  • Celgene Corporation

  • Johnson & Johnson

  • CooperSurgical Inc.

  • LiNA Medical USA

  • Conceptus Inc.

  • Hologic Inc.

  • Karl Storz GmbH & Co. Kg,

  • Boston Scientific Corporation


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers